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Early detection of fibrosis is important in identifying individuals at risk for advanced liver dis-
ease in non-alcoholic fatty liver disease (NAFLD). We tested whether second-harmonic
generation (SHG) and coherent anti-Stokes Raman scattering (CARS) microscopy, detect-
ing fibrillar collagen and fat in a label-free manner, might allow automated and sensitive
quantification of early fibrosis in NAFLD.
Methods
We analyzed 32 surgical biopsies from patients covering histological fibrosis stages 0–4,
using multimodal label-free microscopy. Native samples were visualized by SHG and
CARS imaging for detecting fibrillar collagen and fat. Furthermore, we developed a method
for quantitative assessment of early fibrosis using automated analysis of SHG signals.
Results
We found that the SHGmean signal intensity correlated well with fibrosis stage and the mean
CARS signal intensity with liver fat. Little overlap in SHG signal intensities between fibrosis
stages 0 and 1 was observed. A specific fibrillar SHG signal was detected in the liver paren-
chyma outside portal areas in all samples histologically classified as having no fibrosis. This
signal correlated with immunohistochemical location of fibrillar collagens I and III.
Conclusions
This study demonstrates that label-free SHG imaging detects fibrillar collagen deposition in
NAFLD more sensitively than routine histological staging and enables observer-indepen-
dent quantification of early fibrosis in NAFLD with continuous grading.
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Introduction
The subset of patients with NAFLD who have fibrosis (any stage) are at increased risk of liver-
related death [1,2]. While detection of advanced fibrosis rarely constitutes a diagnostic prob-
lem, quantification of early stage(s) of fibrosis is challenging. Noninvasive techniques discrimi-
nate subjects with advanced fibrosis vs. normal liver parenchyma relatively well but are not
able to accurately differentiate between minimal or moderate stages of fibrosis, for which liver
biopsy remains a golden standard [3,4]. In a recent study by Bedossa et al, the same biopsy
from 40 patients, who had metabolic syndrome as the only clinical risk factor for chronic liver
disease, was scored by six expert liver pathologists using the recently developed SAF (steatosis,
activity, fibrosis) scoring system [5]. While concordances for steatosis and activity based on the
kappa index (κ) were substantial (κ = 0.61 and κ = 0.75), that for fibrosis was moderate (κ =
0.53). The major disagreement in fibrosis staging was observed amongst stage 1 subgroups.
These data imply that there is a need for a sensitive, observer-independent tool to detect early
fibrosis in NAFLD.
Nonlinear imaging entails several optical microscopy techniques that enable sensitive detec-
tion of native structures in cells and tissues without exogenous labels. In particular, second-har-
monic generation (SHG) is a non-resonant process that takes advantage of a coherent optical
signal generated by non-centrosymmetric structures, such as fibrillar collagen [6]. Coherent
anti-Stokes Raman scattering (CARS), on the other hand, produces images based on character-
istic intrinsic vibrational frequencies of chemical bonds. Strong resonant CARS signals are gen-
erated from lipids due to their abundant CH2 hydro-carbon bonds [7,8]. Thus, SHG and CARS
imaging can be employed for sensitive detection of fibrosis and fat from tissues in a label-free
fashion. The potential of SHG imaging to detect human liver fibrosis has been examined in
patients with fibrosis due to hepatic B and C infection [9,10]. In Gailhouste et al, the SHG sig-
nal was closely correlated with the intensity of fibrillar collagen I and III stainings and the
Metavir fibrosis score. In both studies, the authors developed methods for scoring the SHG
signal, which was suggested to allow reproducible quantification of fibrosis independently of
operators [9,10].
In NAFLD, fat initially accumulates around the central vein in zone 3. In this area, which
has lower levels of oxygen than the periportal area [11], hepatocytes undergo ballooning necro-
sis and stellate cells become activated in the perisinusoidal areas, leading to fibrogenesis. Fibro-
sis develops as an imbalance between extracellular matrix deposition and degradation. How
these dynamic changes are reflected in clinical disease outcome, is uncertain [12]. Moreover,
there are disease-specific pathways of fibrosis, and fibrotic changes in fatty liver are distinct
from those in hepatitis, which is initially observed in portal areas [12,13]. This emphasizes the
need to develop distinct scoring systems for fibrosis in chronic viral hepatitis and NAFLD [14].
Until now, there are no data available on the utility of SHG imaging in NAFLD. In the pres-
ent proof-of concept study, we wished to determine whether it is possible to develop an auto-
mated analysis of liver fibrosis in NAFLD and whether the use of SHG imaging might be able
to detect early, subtle signs of fibrosis better than routine histopathology.
Materials and Methods
Study subjects
The patients underwent a metabolic study for clinical characterization approximately one
week prior to the liver biopsy, which was taken during bariatric surgery. Subjects were eligible
if they met the following criteria: (a) age 18 to 75 years; (b) no known acute or chronic disease
except for obesity or type 2 diabetes on the basis of medical history, physical examination and
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standard laboratory tests (blood counts, serum creatinine, electrolyte concentrations); (c) alco-
hol consumption less than 20 g per day and less than 30 g for men; (d) no clinical or laboratory
evidence of other liver disease. Patients were excluded if they were pregnant. The study proto-
col was approved by the ethics committee of the Helsinki University Central Hospital and fol-
lows the 1975 Declaration of Helsinki guidelines. Each participant provided written informed
consent. At the metabolic visit, a blood sample was taken after an overnight fast for the screen-
ing laboratory tests (vide supra) as well as for measurement of fasting plasma glucose, serum
insulin, fS-LDL cholesterol, total serum cholesterol, fS-HDL cholesterol, fS-triglycerides,
fS-AST, fS-ALT, and fS-GGT concentrations as described [15]. Body weight and height, waist
and hip circumferences, blood pressure and the electrocardiogram were recorded as described
[15].
Liver biopsies
Wedge biopsies of the liver (50–150 mg) were taken at laparoscopic surgery. Approximately
one-half of the liver sample was fixed in formalin and sent to the pathologist, who was unaware
of the SHG-scoring data, for histopathological assessment, whereas the rest was immediately
frozen and stored in liquid nitrogen. The sample frozen in liquid nitrogen was embedded in
optimal cutting temperature (OCT) compound and cryosectioned at 20μm thickness. Slices
were fixed with 4% paraformaldehyde for 60 min and a coverslip added. The prepared slides
were stored at -20°C for no longer than a week prior to examination by non-linear microscopy.
Histological assessment
NASH was defined according to the scoring system proposed by Kleiner et al. [14]. For histo-
logic analysis, tissue sections were stained with hematoxylin and eosin, impregnated with silver
for reticulin framework, and stained with trichrome for collagen. All biopsy samples were rep-
resentative and most of them had more than 20 portal tracts (a minimum of 6 portal tracts).
The amount of steatosis, inflammation and fibrosis was analyzed. The percentage of steatotic
hepatocytes containing micro- and macrovesicular fat was scored. Inflammatory activity
(included foamy degeneration of hepatocytes, sinusoidal fibrosis and neutrophil infiltration) of
steatohepatitis was scored from 0–3. The stage of fibrosis was scored from 0–4: (0: no fibrosis,
1: portal or sinusoidal fibrosis without bridging septa, 2: portal or sinusoidal fibrosis with few
bridging septa, 3: advanced fibrosis with numerous septa, and 4: fully developed cirrhosis).
Any overlap pathology was ruled out. Every sample was assessed by two pathologists, the clini-
cal pathologist making the original histological diagnosis and the research pathologist indepen-
dently re-evaluating the samples. Their inter-rater agreement for fibrosis stage was 0.39.
Non-linear microscopy
Images were acquired with a commercial Leica TCS SP8 CARS confocal microscope. The
instrument consists of an inverted microscope equipped with an ultra-short pulsed light source
(picoEmerald, APE, Berlin, Germany) that produces the two synchronous beams needed for
CARS microscopy. The Stokes beam at 1064 nm was emitted from a neodymium-doped
yttrium orthovanadate (Nd:YVO4) laser while a tunable pump/probe beam at 780–940 nm
was generated by an optical parametric oscillator (OPO). The pulse width was 5–7 ps with a
repetition rate of 80MHz corresponding to the Raman line width of 2–3 cm-1. The pulses from
the two sources were temporally and spatially overlapped on the focal plane of the microscope.
Up to 100 mW of average power from both the pump and the Stokes source was delivered to
the sample. No signs of photodamage as assessed in [16] were observed with these scanning
parameters. All samples were imaged with identical laser intensity and previously imaged
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samples were used as a reference. The generated SHG and CARS signals passed through suit-
able bandpass filters and were detected in the forward-direction using a non-descanned photo-
multiplier tube (PMT) detector. For SHG imaging the laser was set up at a wavelength of
816.5nm. The same laser was used for the CARS modality simultaneously with the Stokes
beam at 1064 nm to excite the symmetric vibrational resonance of the CH2 hydro-carbon
bonds at 2845 cm-1. Images were acquired from unstained slides using a 25x water immersion
objective (Leica HCX IR APO L 25X/0.95 W). To cover the area of the entire biopsy specimen
(about 4 x 4 mm), multi-tile scanning (up to 25x25 tiles) was performed. All images were
recorded using the Leica Application Suite Advanced Fluorescence (LAS AF) software.
Image analysis
The images were processed and analyzed using Fiji [17]. Background signal, determined as
mean signal intensity outside of the sample, was subtracted, after which the sample mean
SHG-intensity was measured (portal areas and capsule excluded). An algorithm using itera-
tions of mean filtering, thresholding and particle analysis was developed to recognize and
exclude the capsule and portal areas from the measurements (see below for details). Image
analysis was divided into three parts: A) determining sample borders, B) determining the portal
areas, C) measuring signal intensities.
1. Determining sample borders: The signals acquired from the SHG and CARS channels were
overlayed to highlight the sample area. The image was then auto-thresholded by the percen-
tile method [18] and converted to a binary mask. Iterations of filtering were then performed
to smoothen the image (mean, maximum and mean filtering with radii of 50μm, 15μm and
50μm). This 8-bit image was then thresholded (9.8% of maximum pixel intensity) to yield
the final area.
2. Determining portal areas: The SHG channel was extracted from the image. To remove back-
ground, the 32-bit image was auto-thresholded to mean intensity. Next, iterations of filter-
ing were used to harmonize the highly fibrillar structure of collagen fibrils (mean,
maximum and mean filtering with radii 15μm, 35μm and 25μm). Finally, the image was
thresholded (1.17% of maximum pixel intensity) for particle analysis. Recognized particles
were filtered with loose size and roundness parameters.
3. Measuring signal intensities: The background signal of the original image was first removed,
by subtracting the mean signal intensity outside of the sample (recognized in step A). Mean
SHG- and CARS-signal intensities were then measured after excluding the portal areas and
the capsule.
Immunofluorescence microscopy
Human tissue samples were analyzed using a basic immunofluorescence protocol for formalin-
fixed and paraffin-embedded tissue sections. In brief, 5-μm sections underwent xylene/ethanol
rehydration series and were blocked with 1% BSA in PBS (pH 7.2) for 1h, incubated with a pri-
mary antibody overnight at 4°C and with the secondary antibody for 1 hour at room tempera-
ture. All washes were performed with PBS. The following primary antibodies were used with
the dilutions indicated: collagen I (600-401-103, Rockland Immunochemicals, Limerick, PA,
USA, 1:800) and collagen III (600-401-105, Rockland Immunochemicals, 1:400). Before stain-
ing, epitope retrieval was performed by a heat-mediated method for 15 min with sodium citrate
buffer (pH 6.0). Anti-rabbit Cy3 (Jackson Immunoresearch, West Grove, PA, USA, 1:300) was
used as a secondary antibody. For negative control stainings, the primary antibodies were
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omitted and replaced by PBS. Immunostaining with different antibodies was performed on
parallel sections.
Statistics
For the patient data, continuous variables were tested for normality using the Kolmogorov-
Smirnov test. Normally distributed data were reported in means ± SEM while non-normally
distributed were reported in medians and interquartile ranges. For the microscopy data, the
Mann-Whitney-U test was used to estimate statistical significance. Inter-rater agreement was
evaluated using the weighted kappa score. Statistical analyses were performed using IBM SPSS
Statistics 22.0.0.0 version (IBM, Armonk, NY).
Results
Patients
A total of 32 patients were studied, of whom 11 were men and 21 were women. The mean BMI
of the subjects was 47.2 ± 1.0 kg/m2 and the median age 47.5 (41.5–58.0) years. Their key labo-
ratory findings are summarized in Table 1. In liver histology, the median proportion of hepato-
cytes with macrovesicular steatosis averaged 20 (10–39) %. The distribution of fibrosis stage (0/
1/2/3/4) among the subjects was: 12 (37.5%), 11 (34.4%), 5 (15.6%), 3 (9.4%) and 1 (0.03%);
and for steatosis grade (0/1/2/3): 19 (59.4%), 8 (25%), 3 (9.4%) and 2 (6.3%).
Sample preparation and multimodal label-free imaging of liver biopsies
An overview of the preparation of biopsies for SHG and CARS imaging and the timeline is
shown in Fig 1A. Freshly frozen biopsies were cryosectioned, followed by immediate mild fixa-
tion of the sections in 4% paraformaldehyde, to minimize sample manipulation. Imaging was
performed on a confocal microscope capable of both SHG and CARS imaging, using near-
infrared laser excitation at 816.4 nm and 1064.5 nm, and taking advantage of the characteristic
changes in the photon energy states (Fig 1B). The entire biopsy (typically about 4x4 mm) was
imaged, with up to 25 x 25 overlapping squares and the images stitched together (Fig 1C). An
example of a mosaic image of a biopsy after simultaneous recording of SHG and CARS signals
and reconstruction of the data set to display the entire specimen is shown in Fig 1D.
Table 1. Key laboratory findings of the study subjects.
Total All subjects (n = 32)
fP-Glucose (mmol/l) 6.1 (5.5–6.8)
fS-Insulin (mU/l) 16.3 ± 1.5
fP-Total cholesterol (mmol/l) 4.0 ± 0.2
fP-Triglycerides (mmol/l) 1.46 ± 0.1
fP-HDL cholesterol (mmol/l) 1.20 ± 0.1
fP-LDL cholesterol (mmol/l) 2.3 ± 0.1
P-AST (IU/l) 32 (27–40)
P-ALT (IU/l) 34 (27–52)
P-GGT (U/l) 30 (20–58)
Data are in means ± SEM or median (25th-75th percentile), as appropriate.
doi:10.1371/journal.pone.0147804.t001
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Fig 1. Sample processing steps, SHG and CARS imaging of NAFLD biopsy. A. Workflow and estimated time required for analysis steps. B. Schematic
diagram of the SHG and CARS principles. In the SHG process, the energy of two pump photons (yellow arrows) is combined to produce one emission photon
(green arrow). In the CARS process, the pump (yellow arrows) and the Stokes laser (blue arrow) stimulate a selected molecular vibration. Probing of this
vibration with the second pump photon results in the CARS emission (red arrow). Dotted lines represent virtual states of excitation. C. Biopsy reconstruction
from stitched images. D. Simultaneous SHG and CARS imaging of a NAFLD biopsy, separate channels and the overlay are shown. Scale bar 500um.
doi:10.1371/journal.pone.0147804.g001
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Relationship between histologic fibrosis stage with the SHG and
steatosis grade with the CARS signal
To analyze if the SHG signal intensity correlated with histological fibrosis staging, we analyzed
32 samples, from which parallel samples had been histologically evaluated by a pathologist. As
the patients were undergoing bariatric surgery, advanced stages of fibrosis (3 and 4) were rare
in this material. Examples of SHG images of stage 0–4 fibrosis are shown in Fig 2A. In stages
1 and 2, the signal from the portal areas typically predominated, while in stages 3 and 4,
marked signals were also observed in septal regions, in agreement with the expected distribu-
tion of fibrosis in these stages. Moreover, there was a good overall correlation between the
mean intensity of the SHG signal and fibrosis stage in all samples (Fig 2B). In the same sam-
ples, the mean signal intensity of the CARS signal correlated positively with histologically
determined macroscopic steatosis (Fig 2C).
Development of automated image analysis for early fibrosis
We next developed an automated image analysis method to evaluate and quantify early liver
fibrosis from the biopsies using SHG. To this end, we excluded SHG signals derived from the
capsule and from portal areas. This is because these regions generate a prominent SHG signal
even in a normal liver, due to their physiologically high collagen content, and this masks any
weaker signal from elsewhere in the parenchyma. Furthermore, the area occupied by portal
regions and the capsule varied considerably between biopsies, affecting signal mean intensity.
The automatic procedure developed for exclusion of these areas involved background subtrac-
tion and thresholding, filtering, particle identification and exclusion, prior to SHG and CARS
intensity measurements in the remaining area, is illustrated in S1 Fig.
Detection and characterization of early parenchymal fibrosis using SHG
imaging
The SHG signal derived from the liver parenchyma and included in the analysis was fibrillar in
nature (Fig 3). Remarkably, we found that already stage 0 NAFLD samples showed specific,
albeit weak, fibrillar SHG signals. These were typically relatively short (20–200 micron length)
wavy fibrils or narrow bundles of fibrils (Fig 3A and 3B). In stage 1, the signal was essentially
similar in character but these thin threads were more densely distributed between cords of
hepatocytes, resulting in an overall higher SHG signal (Fig 3C and 3D). The fibrils often
appeared to bridge between portal areas (excluded from the analysis, black regions within tis-
sue section in Fig 3), reminiscent of early septal fibrosis (Fig 3B, insets 2 and 3). The fibrils
were interspersed between heterogeneously sized lipid deposits as visualized by the CARS sig-
nal. This signal derives from lipid-laden hepatocytes.
To assess if the SHG signal in early fibrosis is specific and derives from collagens, we per-
formed indirect immunofluorescence stainings of stage 0 fibrosis NAFLD samples using anti-
collagen antibodies. The samples were imaged using both fluorescence and SHG channels. Due
to solvent exposure during processing, lipids were extracted in these samples and lipid-rich
areas appeared as holes in the specimen. We found specific immunoreactivity for the major
fibrillar collagens I and III, with prominent labelling of collagen I in the extracellular matrix
surrounding the central vein and the portal area (Fig 4A). The collagen III signal concentrated
in the same areas but was weaker, presumably due to lower abundance of collagen III and/or
weaker antibody affinity. Importantly, both collagen signals overlapped with the SHG signal in
the same areas (Fig 4), demonstrating specificity of the SHG signal. Moreover, SHG imaging
revealed multiple thin threads that emanated from the central vein but were not highlighted by
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the antibody stainings (Fig 4B), suggesting that SHG microscopy is more sensitive than colla-
gen immunostaining in detecting early fibrosis.
Fig 2. Correlation of SHG intensity with liver fibrosis and CARS intensity with liver fat. A. Exemplary SHG and CARS images of fibrosis stages 0–4.
Scale bar 500μm. B. SHGmean intensity in samples representing different fibrosis stages, stage 0 n = 12, stage 1 n = 12, stage 2 n = 4, stage 3 n = 3, stage 4
n = 1, *p<0.05 between stages 0 and 1 and between 1 and 2. C. CARSmean intensity in samples (n = 32) representing different amounts of macrovesicular
fat as assessed by pathologist; Spearman’s rank correlation coefficient 0.504, p<0.005.
doi:10.1371/journal.pone.0147804.g002
Quantification of Early Fibrosis in NAFLD
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SHG imaging reveals positive signals in stage 0 fibrosis
We examined whether the automated SHG imaging system can be used for detection of early
fibrosis and whether it correlates with the stage of fibrosis as determined by histology. For this,
we compared the SHG signal from 24 NAFLD samples with the degree of fibrosis (stage 0 or
Fig 3. High-resolution imaging of fibrillar and lipid signals in NAFDL stage 0 and stage 1 fibrosis. A. Stage 0 fibrosis, B. Higher magnification insets
(1–4) shown as white rectangles in A. C. Stage 1 fibrosis. D. Higher magnification insets (5–8) shown as white rectangles in C. Scale bar 500μm in A and C,
and 50μm in B and D.
doi:10.1371/journal.pone.0147804.g003
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Fig 4. Immunofluorescence and SHG detection of collagens in NAFLD stage 0 fibrosis. Immunofluorescence (IF) stainings of collagens type I and III
displayed as red and SHG signals from the same sections displayed as green, colocalization is displayed as yellow in the overlay image. White rectangle in A
shows the position of insets highlighted in B. Asterisk indicates a portal triad. Arrows indicate examples of fine SHG signals not evident by collagen
immunostaining. Scale bar: 50μm.
doi:10.1371/journal.pone.0147804.g004
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1). This analysis showed that on average, stage 1 samples had significantly higher SHG intensi-
ties than stage 0 samples (Fig 5A and 5B), indicating that SHG imaging can differentiate
between these stages of fibrosis. SHG imaging showed a roughly 5-fold difference in signal
mean intensity within the stage 1 samples (Fig 5A). Three stage 0 samples (independently
scored as stage 0 fibrosis by two pathologists) had higher SHG intensities than the lowest stage
1 sample, and one of them had a higher intensity than stage 1 samples on average (Fig 5A).
The average SHG signal intensity in stage 0 fibrosis samples was approximately 8-fold above
background (Fig 5B). This suggests that SHG imaging can detect early fibrosis in NAFLD
more sensitively than routine histological staging.
Discussion
In this study, we tested the capability of a recently established label-free imaging modality,
SHG microscopy, in assessing the initial stages of fibrosis in NAFLD. Our findings provide evi-
dence that SHG imaging can detect early deposition of fibrillar compounds better than routine
histopathology. SHG seems to improve the detection sensitivity for very fine fibrillary struc-
tures, apparently representing the earliest signs of fibrosis, and enables quantitative assessment
of these signals with continuous grading. We also demonstrate the capability of a new, in-
house developed automated image analysis platform in providing observer-independent quan-
tification of early fibrosis. This is relevant as there is considerable inter-rater disagreement in
fibrosis staging, especially in early stages of fibrosis in NAFLD [5].
SHG imaging has previously been used to quantify liver fibrosis in patients with hepatitis B
and C [9,10]. Gailhouste et al. [9] developed a quantitative SHG scoring method that was par-
ticularly suited for assessing advanced fibrosis. They demonstrated the capability of SHG
microscopy in discriminating advanced fibrosis and cirrhosis. Instead, in non-advanced (Meta-
vir F0-F1) fibrosis, the SHG indices overlapped. The authors also reported a good relationship
between SHG signal and collagens over-produced during fibrosis progression, in agreement
with our study. Recently, Xu et al. [10] developed another SHG based scoring method that dif-
ferentiated between Metavir stages F1-4 in chronic hepatitis B. This comprised 12 samples
with F1 and 9 with F2 fibrosis; however, F0 samples were not included in this cohort.
The present report provides, to our knowledge, the first assessment of early fibrosis in
NAFLD using SHG imaging. It is important to note that the location and distribution of fibro-
sis—and thereby SHG signal generation—depends on the etiology of liver disease. In chronic
hepatitis, the inflammatory activity is typically dominating in the interface area of portal tracts
and lobules, inducing fibrosis that is primarily periportal [13]. Instead, in steatohepatitis the
overall location of the degenerative process is different: NASH activity is mainly located in the
pericentral region and activated stellate cells play a major role in forming the characteristic
sinusoidal fibrosis [19–21].
In normal liver, several of the major collagens, such as IV and VI, are non-fibrillar and
therefore not expected to generate prominent SHG signals. Instead, the major fibrillar colla-
gens, types I and III, are expressed upon development of liver fibrosis. Their amounts increase
in NAFLD related fibrosis [22,23] and give raise to SHG signals [24], as demonstrated in the
present study. Of the other fibrillar collagens expressed in the liver, type V collagen is consider-
ably less abundant and assembles with type I and III collagens to form composite, heterotypic
fibrils. When fibrosis advances to cirrhosis, all these fibrillar collagen types increase signifi-
cantly [25].
SHG imaging offers a number of advantages in comparison to traditional histological
assessment of fibrosis. Firstly, sample preparation is fast as it does not require de-waxing
or other lengthy preparation steps. Secondly, it provides sensitive, quantitative and
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operator-independent assessment of fibrosis that can be automated. This enables reliable mon-
itoring of incipient extracellular matrix deposition, which has until now been difficult to reli-
ably quantify. Thirdly, SHG imaging requires no staining and directly detects fibrillar
Fig 5. SHG imaging provides quantitative assessment and detects fibrosis in stage 0 NAFLD.Mean SHG intensities from individual NAFLD biopsies
analyzed using automated signal analysis. In A, arrows indicate the F0 and F1 samples shown in Fig 3 and dashed lines show average intensities of stage 0
and 1 samples. B. Comparison of SHGmean intensity in stage 0 and 1 fibrosis. Dashed line indicates average background SHG signal intensity from outside
the sample area. ***p<0.001.
doi:10.1371/journal.pone.0147804.g005
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supramolecular structures, due to their inherent physical properties of non-centrosymmetry
and high crystalline structure [24]. This is in contrast to traditional histological stains used for
the detection of extracellular matrix, including collagen, and based on indirect methods (such
as acidity, properties of incorporated contrasting dyes or metal ions). Finally, combination of
SHG with other non-linear and linear optical modalities is straightforward, as demonstrated
here by combining SHG with CARS or immunofluorescence microscopy. SHG imaging also
has some limitations: commercial instruments are rather costly and require a skilled operator
to set up. However, prices tend to go down once techniques become more routine and once
established, SHG imaging is relatively simple to perform.
In the future, the automated SHG quantification method developed should be validated in
additional patient cohorts. Particularly relevant are samples with mimimal or no histochemi-
cally detectable fibrosis, for which this method might provide added value. It would also be
interesting to adopt SHG imaging for the examination of repeated liver biopsies, in combina-
tion with multimodal follow-up of fat deposition by CARS and inflammatory cell accumulation
e.g. by immunofluorescence detection. Where paired biopsies are available, SHG imaging has
significant potential for improved assessment of fibrosis progression or regression compared to
currently employed techniques. With increased sensitivity and quantitativeness for fibrosis
assessment, SHG imaging should help to better define the dynamic nature of fibrosis, including
the efficacy of drug or other therapy responses.
In conclusion, this study demonstrates that label-free SHG imaging enables observer-inde-
pendent quantitative detection of early fibrosis in NAFLD with continuous grading. Impor-
tantly, SHG imaging was more sensitive than routine histological staging in detecting the early
fibrotic processes in NAFLD. This feasibility study provides a basis for employing this method
in larger NAFLD patient cohorts.
Supporting Information
S1 Fig. Overview of automated image analysis procedure. Exemplary images of analysis
steps. A. Overlay of background subtracted CARS and SHG images. B. Filtered image. C. Fil-
tered areas for exclusion. D. Final image for analysis. White line indicates the sample area and
green lines excluded portal areas.
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